59 related articles for article (PubMed ID: 9843440)
1. Characterization of the extracellular ligand-binding domain of the type II activin receptor.
Greenwald J; Le V; Corrigan A; Fischer W; Komives E; Vale W; Choe S
Biochemistry; 1998 Nov; 37(47):16711-8. PubMed ID: 9843440
[TBL] [Abstract][Full Text] [Related]
2. Three-finger toxin fold for the extracellular ligand-binding domain of the type II activin receptor serine kinase.
Greenwald J; Fischer WH; Vale WW; Choe S
Nat Struct Biol; 1999 Jan; 6(1):18-22. PubMed ID: 9886286
[TBL] [Abstract][Full Text] [Related]
3. Activin and inhibin binding to the soluble extracellular domain of activin receptor II.
Donaldson CJ; Vaughan JM; Corrigan AZ; Fischer WH; Vale WW
Endocrinology; 1999 Apr; 140(4):1760-6. PubMed ID: 10098513
[TBL] [Abstract][Full Text] [Related]
4. Expression and purification of the extracellular ligand-binding domain of the atrial natriuretic peptide (ANP) receptor: monovalent binding with ANP induces 2:2 complexes.
Misono KS; Sivasubramanian N; Berkner K; Zhang X
Biochemistry; 1999 Jan; 38(2):516-23. PubMed ID: 9888790
[TBL] [Abstract][Full Text] [Related]
5. Expression of the human activin type I and II receptor extracellular domains in Pichia pastoris.
Daly R; Hearn MT
Protein Expr Purif; 2006 Apr; 46(2):456-67. PubMed ID: 16309921
[TBL] [Abstract][Full Text] [Related]
6. Activin receptors: cellular signalling by receptor serine kinases.
Zimmerman CM; Mathews LS
Biochem Soc Symp; 1996; 62():25-38. PubMed ID: 8971337
[TBL] [Abstract][Full Text] [Related]
7. Betaglycan binds inhibin and can mediate functional antagonism of activin signalling.
Lewis KA; Gray PC; Blount AL; MacConell LA; Wiater E; Bilezikjian LM; Vale W
Nature; 2000 Mar; 404(6776):411-4. PubMed ID: 10746731
[TBL] [Abstract][Full Text] [Related]
8. Effect of adenovirus-mediated overexpression of follistatin and extracellular domain of activin receptor type II on gonadotropin secretion in vitro and in vivo.
Leal AM; Takabe K; Wang L; Donaldson CJ; MacConell LA; Bilezikjian LM; Verma IM; Vale W
Endocrinology; 2002 Mar; 143(3):964-9. PubMed ID: 11861519
[TBL] [Abstract][Full Text] [Related]
9. The structure of the follistatin:activin complex reveals antagonism of both type I and type II receptor binding.
Thompson TB; Lerch TF; Cook RW; Woodruff TK; Jardetzky TS
Dev Cell; 2005 Oct; 9(4):535-43. PubMed ID: 16198295
[TBL] [Abstract][Full Text] [Related]
10. Identification of a binding site on the type II activin receptor for activin and inhibin.
Gray PC; Greenwald J; Blount AL; Kunitake KS; Donaldson CJ; Choe S; Vale W
J Biol Chem; 2000 Feb; 275(5):3206-12. PubMed ID: 10652306
[TBL] [Abstract][Full Text] [Related]
11. Functional antagonism between activin and osteogenic protein-1 in human embryonal carcinoma cells.
Piek E; Afrakhte M; Sampath K; van Zoelen EJ; Heldin CH; ten Dijke P
J Cell Physiol; 1999 Aug; 180(2):141-9. PubMed ID: 10395283
[TBL] [Abstract][Full Text] [Related]
12. Characterization of the activin receptor in cultured rat hepatocytes.
Zhang YQ; Kanzaki M; Mashima H; Mine T; Kojima I
Hepatology; 1996 Aug; 24(2):446-50. PubMed ID: 8690418
[TBL] [Abstract][Full Text] [Related]
13. Truncated activin type II receptor inhibits erythroid differentiation in K562 cells.
Liu F; Shao LE; Yu J
J Cell Biochem; 2000 Apr; 78(1):24-33. PubMed ID: 10797563
[TBL] [Abstract][Full Text] [Related]
14. Osteoblasts express types I and II activin receptors during early intramembranous and endochondral bone formation.
Shuto T; Sarkar G; Bronk JT; Matsui N; Bolander ME
J Bone Miner Res; 1997 Mar; 12(3):403-11. PubMed ID: 9076583
[TBL] [Abstract][Full Text] [Related]
15. BMP-3 and BMP-6 structures illuminate the nature of binding specificity with receptors.
Allendorph GP; Isaacs MJ; Kawakami Y; Izpisua Belmonte JC; Choe S
Biochemistry; 2007 Oct; 46(43):12238-47. PubMed ID: 17924656
[TBL] [Abstract][Full Text] [Related]
16. Ligand affinity for amino-terminal and juxtamembrane domains of the corticotropin releasing factor type I receptor: regulation by G-protein and nonpeptide antagonists.
Hoare SR; Sullivan SK; Schwarz DA; Ling N; Vale WW; Crowe PD; Grigoriadis DE
Biochemistry; 2004 Apr; 43(13):3996-4011. PubMed ID: 15049707
[TBL] [Abstract][Full Text] [Related]
17. Assembly of TbetaRI:TbetaRII:TGFbeta ternary complex in vitro with receptor extracellular domains is cooperative and isoform-dependent.
Zúñiga JE; Groppe JC; Cui Y; Hinck CS; Contreras-Shannon V; Pakhomova ON; Yang J; Tang Y; Mendoza V; López-Casillas F; Sun L; Hinck AP
J Mol Biol; 2005 Dec; 354(5):1052-68. PubMed ID: 16289576
[TBL] [Abstract][Full Text] [Related]
18. High resolution structures of the bone morphogenetic protein type II receptor in two crystal forms: implications for ligand binding.
Mace PD; Cutfield JF; Cutfield SM
Biochem Biophys Res Commun; 2006 Dec; 351(4):831-8. PubMed ID: 17094948
[TBL] [Abstract][Full Text] [Related]
19. Rodent adrenocortical cells display high affinity binding sites and proteins for inhibin A, and express components required for autocrine signalling by activins and bone morphogenetic proteins.
Farnworth PG; Wang Y; Leembruggen P; Ooi GT; Harrison C; Robertson DM; Findlay JK
J Endocrinol; 2006 Mar; 188(3):451-65. PubMed ID: 16522726
[TBL] [Abstract][Full Text] [Related]
20. Bone morphogenetic protein (BMP) ligands and receptors in bovine ovarian follicle cells: actions of BMP-4, -6 and -7 on granulosa cells and differential modulation of Smad-1 phosphorylation by follistatin.
Glister C; Kemp CF; Knight PG
Reproduction; 2004 Feb; 127(2):239-54. PubMed ID: 15056790
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
